Aprotinin and deep hypothermic circulatory arrest: There are no benefits even when appropriate amounts of heparin are given

European Journal of Cardio-thoracic Surgery

Volumn 11, Issue 1, 1997, Pages 149-156

  Parolari, Alessandro ^a   Antona, Carlo ^a   Alamanni, Francesco ^a   Spirito, Rita ^a   Naliato, Moreno ^a   Gerometta, Piersilvio ^a   Arena, Vincenzo ^a   Biglioli, Paolo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Aprotinin; Circulatory arrest; Deep hypothermia; Unfavourable events

Indexed keywords

APROTININ; HEPARIN;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL ARTICLE; FEMALE; HEART ARREST; HEART INFARCTION; HUMAN; HYPOTHERMIA; MALE; PRIORITY JOURNAL;

AGED; ANEURYSM, DISSECTING; AORTIC ANEURYSM, THORACIC; APROTININ; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; CAUSE OF DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART ARREST, INDUCED; HEPARIN; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; REOPERATION; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 0031053231     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1010-7940(96)01022-6     Document Type: Article

References (26)

1. Alamanni F, Agrifoglio M, Pompilio G, Spirito R, Sala A, Arena V, Roberto M, Biglioli P. Aortic arch surgery: pros and cons of selective verebral perfusion. A multivariable analysis for cerebral injury during hypothermie circulatory arrest. J Cardiovasc Surg 1995;36:31-37.
2. Bidstrup BP, Royston D, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin. J Thorac Cardiovasc Surg 1989;97:364-372.
3. Blauhaut B, Gross C, Necek S, Doran JE, Spath P, Lunsgard-Hansen P. Effects of high-dose aprotinin on blood loss, platelet function fibrinolysis, complement, and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991;101:958-967.
4. Bohrer H, Fleischer F, Lang J, Vahl C. Early formation on pulmonary artery catheters in cardiac surgical patients receiving high-dose aprotinin. J Cardiothorac Vasc Anaesth 1990;4:222-225.
5. Cosgrove DM III, Heric B, Lytle BW, Taylor PC, Novoa R, Golding La, Stewart RW, McCarthy PM, Loop FD. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 1992;54:1031-1038.
6. de Smet AAEA, Joen MCN, van Oeveren W, Roozendaal KJ, Harder MP, Eijsman L, Wildevuur CRH. Increased anticoagulation during cardiopulmonary bypass by aprotinin. J Thorac Cardiovasc Surg 1990;100:520-527.
7. Havel MP, Griesmacher A, Weigel G, Owen A, Simon P, Muller MM, Wolner E. Aprotinin decreases release of 6-ketoprostaglandin F1a and increases release of thromboxane B2 in cultured human umbilical vein endothelial cells. J Thorac Cardiovasc Surg 1992;104:654-658.
8. Huyzen RJ, Harder MP, Gallandat Huet RCG, Boonstra PW, Njo TL, Brenken U, van Oeveren W. Alternative perioperative anticoagulation monitoring during cardiopulmonary bypass in aprotinin-treated patients. J Cardiothorac Vasc Anesth 1994;8:153-156.
9. Hunt BJ, Segal H, Yacoub M. Aprotinin and heparin monitoring during cardiopulmonary bypass. Circulation 1994;86(Suppl II):II410-II412.
10. Matalanis G, Buxton B. Retrograde vital organ perfusion during aortic arch repair. Ann Thorac Surg 1993;56:981-984.
11. Mannucci L, Gerometta P, Mussoni L, Antona C, Parolari A, Salvi L, Biglioli P, Tremoli E. One month follow-up of haemostatic variables in patients undergoing aortocoronary bypass surgery. Thromb Haemost 1995;73:356-361.
12. Najman DM, Walenga J, Fareed J, Pifarré R. Effects of aprotinin on anticoagulant monitoring: implications in cardiovascular surgery. Ann Thorac Surg 1993;55:662-666.
13. Parolari A, Antona C, Gerometta P, Alamanni F, Spirito R, Arena V, Sala A, Biglioli P. The effect of 'high dose' aprotinin and other factors on bleeding and reoperations in adult coronary and valve operations: an analysis of 2190 patients during a five-year period (1987-1991). Fur J Cardiothorac Surg 1995;9:77-82.
14. Parolari A, Antona C, Rona P, Gerometta P, Huang F, Alamanni F, Arena V, Biglioli P. The effect of multiple blood conservation techniques on donor blood exposures in adult coronary and valve surgery performed with a membrane oxygenator: a multivariable analysis on 1310 patients. J Card Surg 1995;10:101-109.
15. Royston D. High-dose aprotinin therapy: a review of the first five years' experience. J Cardiothorac Vasc Anesth 1992;6:76-100.
16. Sundt TM III, Kochoukos NT, Saffitz JE, Murphy SF, Wareing TH, Stahl DJ. Renal dysfunction and intravascular coagulation with aprotinin and hypothermie circulatory arrest. Ann Thorac Surg 1993;55:1418-1424.
17. van Oeveren W, Harder MP, Roozendal KJ, Eijsman L, Wildevuur CRH. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990;99:788-797.
18. Wang JS, Lin CY, Hung WT, Thisted RA, Karp RB. In vitro effects of aprotinin on activated clotting time measured with different activators. J Thorac Cardiovasc Surg 1992;104:1135-1140.
19. Wang JS, Lin CY, Hung WT, Karp RB. Monitoring of heparin-induced anticoagulation with kaolin-activated clotting time in cardiac surgical patients treated with aprotinin. Anaesthesiology 1992;77:1080-104.
20. Westaby S. Aprotinin in perspective. Ann Thorac Surg 1993;55:1033-1041.
21. Westaby S, Forni A, Dunning J, Giannopulos N, O'Reagan G, Drossos G, Pillai R. Aprotinin and bleeding during profoundly hypothermie perfusion. Fur J Cardio-thorac Surg 1994;8:82-86.
22. Wildevuur CRH, Eijsman L, Roozendaal KJ, Harder MP, Chang M, van Oeveren W. Platelet preservation during cardiopulmonary bypass with aprotinin. Eur J Cardiothorac Surg 1989;3:533-538.
23. Bidstrup B, Underwood S, Sapsford R. Effect of aprotinin (trasylol) on aorta-coronary bypass graft patency. J Thorac Cardiovasc Surg 1993;105:147-153.
24. Fremes S, Wong B, Lee F, Ryan M, Christakis G, McLean R, Goldman B, Naylor C. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg 1994;58:1580-1588.
25. Havel M, Grabenwoger F, Schneider J, Laufer G, Wollenek G, Owen A, Simon P, Teufelsbauer H. Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. J Thorac Cardiovasc Surg 1994;107:807-810.
26. Lemmer J, Stanford W, Bonney S, Breen J, Chomka E, Eidridge W, Holt W, Karp R, Laub G, Lipton N, Schaff H, Tatooles C, Rumberger J. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. J Thorac Cardiovasc Surg 1994;107:543-553.